[Translation] A randomized, open-label, single-dose, two-sequence, two-period, crossover, fasting bioequivalence study of fosfomycin tromethamine granules (3 g) developed by Jiangsu Lianhuan Pharmaceutical Co., Ltd. and fosfomycin tromethamine granules (3 g) produced by Zambon Switzerland Ltd. in healthy Chinese subjects

以江苏联环药业股份有限公司研制的磷霉素氨丁三醇颗粒（规格：3 g）为受试制剂，以Zambon Switzerland Ltd.生产的磷霉素氨丁三醇颗粒（商品名：Monurol®，规格：3 g）为参比制剂，考察两制剂在空腹状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

Fosfomycin tromethamine granules (specification: 3 g) developed by Jiangsu Lianhuan Pharmaceutical Co., Ltd. were used as the test preparation, and fosfomycin tromethamine granules (trade name: Monurol®, specification: 3 g) produced by Zambon Switzerland Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after a single dose in the fasting state were investigated to evaluate whether the two preparations were bioequivalent; at the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date21 Aug 2024

Sponsor / Collaborator

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

ChiCTR2400084823 / RecruitingPhase 4IIT

Clinical study of Longqing tablets in the treatment of acute uncomplicated lower urinary tract infection

Start Date01 Jun 2024

Sponsor / Collaborator-

NCT05667207 / CompletedNot ApplicableIIT

Dipsticks and Point-of-care Microscopy to Reduce Antibiotic Use in Women With Uncomplicated Urinary Tract Infections: a Cluster-randomized Controlled Pilot Trial

With the aim to pilot a full-scaled trial to reduce unnecessary antibiotics in women with suspected uncomplicated urinary tract infections, twenty general practices in Bavaria, Germany, will be randomized to deliver patient management based on phase-contrast microscopy and urinary dipsticks or to usual care. Primary endpoints are recruitment and retention rates.

Start Date15 Jun 2023

Sponsor / Collaborator

Wuerzburg University Hospital

[+7]

100 Clinical Results associated with Acute urinary tract infection

100 Translational Medicine associated with Acute urinary tract infection

0 Patents (Medical) associated with Acute urinary tract infection

870

Literatures (Medical) associated with Acute urinary tract infection

08 Oct 2024·Antimicrobial Agents and Chemotherapy

Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae

Article

Author: Zhu, Yun-Zhu ; Tian, Ping ; Zhu, Rong-Qing ; Guo, Ming-Juan ; Li, Ya-Sheng ; Guo, Ya-Qin ; Li, Qing-Qing ; Liu, Yan-Yan ; Yang, Yi ; Yu, Liang ; Li, Jia-Bin

ABSTRACT Limited treatment options and multidrug-resistant (MDR) Klebsiella pneumoniae present a significant therapeutic challenge, underscoring the need for novel approaches. Drug repurposing is a promising tool for augmenting the activity of many antibiotics. This study aimed to identify novel synergistic drug combinations against K. pneumoniae based on drug repurposing. We used the clinically isolated GN 172867 MDR strain of K. pneumoniae to determine the reversal resistance activity of zidovudine (AZT). The combined effects of AZT and various antibiotics, including nitrofurantoin (NIT) and omadacycline (OMC), were examined using the checkerboard method, growth curves, and crystal violet assays to assess biofilms. An in vitro combination activity testing was carried out in 12 isolates of K. pneumoniae. In vivo murine urinary tract and lung infection models were used to evaluate the therapeutic effects of AZT + NIT and AZT + OMC, respectively. The fractional inhibitory concentration index and growth curve demonstrated that AZT synergized with NIT or OMC against K. pneumoniae strains. In addition, AZT + NIT inhibited biofilm formation and cleared mature biofilms. In vivo , compared with untreated GN 172867-infected mice, AZT + NIT and AZT + OMC treatment decreased colony counts in multiple tissues ( P < 0.05) and pathological scores in the bladder and kidneys ( P < 0.05) and increased the survival rate by 60% ( P < 0.05). This study evaluated the combination of AZT and antibiotics to treat drug-resistant K. pneumoniae infections and found novel drug combinations for the treatment of acute urinary tract infections. These findings suggest that AZT may exert significant anti-resistance activity.

01 Sep 2024·Medical Clinics of North America

Update on Therapies and Treatments in Women’s Health

Review

Author: Casas, Rachel S ; Walsh, Judith M E ; Prifti, Christine ; Yecies, Emmanuelle ; Merriam, Sarah

This article contains noninclusive language such as "females" and "women" when those terms were used in the research and historic context we are summarizing. New therapies have become available for vasomotor symptoms, postpartum depression, contraception, osteoporosis, recurrent yeast infections, acute and recurrent urinary tract infections, and female hypoactive sexual desire disorder. These therapies meet unique patient needs and change clinical practice for select groups. As is typical for new treatments, insurance coverage and access issues limit the adoption of some therapies.

13 Aug 2024·Microbiology Resource Announcements

Complete genome sequences of paired isogenic Burkholderia pseudomallei isolated from a Thai pediatric patient with a urinary tract infection

Article

Author: Wongsurawat, Thidathip ; Faksri, Kiatichai ; Saninjuk, Kritsakorn ; Patarakul, Kanitha ; Jenjaroenpun, Piroon ; Chirakul, Sunisa ; Suchartlikitwong, Pintip

ABSTRACTBurkholderia pseudomallei is the causative agent of melioidosis, the disease endemic in Southeast Asia and northern Australia. We report complete genome sequences of paired isogenic B. pseudomallei isolated from a 12-year-old Thai male presenting with acute urinary tract infection before (SCBP001) and after (SCBP007) a decrease in susceptibility to ceftazidime.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Acute urinary tract infection

Basic Info

Related

Analysis